Louisiana State Employees Retirement System Makes New $1.19 Million Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Louisiana State Employees Retirement System acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 19,200 shares of the medical equipment provider's stock, valued at approximately $1,190,000.

A number of other hedge funds have also bought and sold shares of the business. Tucker Asset Management LLC boosted its holdings in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 282 shares during the period. First Horizon Advisors Inc. boosted its holdings in Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 225 shares during the period. Covestor Ltd boosted its holdings in Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 203 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 156 shares during the period. Finally, NBC Securities Inc. bought a new position in Lantheus in the 3rd quarter valued at $46,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 94,545 shares of company stock worth $6,169,936. 2.10% of the stock is currently owned by company insiders.

Lantheus Trading Up 2.1 %

NASDAQ:LNTH traded up $1.34 during trading hours on Tuesday, reaching $64.41. The company's stock had a trading volume of 591,933 shares, compared to its average volume of 1,047,826. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of 13.92 and a beta of 0.54. The firm has a 50-day simple moving average of $60.94 and a 200-day simple moving average of $62.78. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts' consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to analysts' expectations of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Research analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on LNTH shares. JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. B. Riley lifted their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a report on Thursday, April 18th. Truist Financial reaffirmed a "buy" rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Saturday, January 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average target price of $104.71.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.